Objectives: To determine the extent and disclosure of financial ties to industry and use of scientific evidence in comments on a US Food and Drug Administration (FDA) regulatory framework for modifications to artificial intelligence/machine learning (AI/ML)-based software as a medical device (SaMD). Design: Cross-sectional study. Setting: We searched all publicly available comments on the FDA ‘Proposed Regulatory Framework for Modifications to Artificial Intelligence/Machine Learning (AI/ML)-Based Software as a Medical Device (SaMD)—Discussion Paper and Request for Feedback’ from 2 April 2019 to 8 August 2019. Main Outcome Measures: The proportion of articles submitted by parties with financial ties to industry, disclosing those ties, ci...
The following manuscript is a scoping literature review which provides a comparative narrative analy...
Contains fulltext : 152571.pdf (publisher's version ) (Open Access)OBJECTIVE: Duri...
Objective: To evaluate clinical trial registration, reporting and publication rates for new drugs by...
In the twentieth century, the Food and Drug Administration (“FDA”) rose to prominence as a respected...
At the beginning of the artificial intelligence (AI)/machine learning (ML) era, the expectations are...
Background: Software as a medical device (SaMD) has gained the attention of medical device regulator...
Objective: To investigate pharmaceutical or medical device industry funding of patient groups. Desig...
Abstract CONTEXT: Disclosure of conflicts of interest (COIs) from pharmaceutical industry study fund...
abstract: The adaptive artificial-intelligence (AI) medical device industry is a novel industry in t...
Protecting and promoting public health is the mission of the U.S. Food and Drug Administration (FDA)...
Background: There has been substantial interest from the pharmaceutical industry to study and develo...
Artificial intelligence (AI) and Machine learning (ML) systems in medicine are poised to significant...
Artificial intelligence (AI) has the potential to make health care more effective and efficient in t...
Objective: To assess the influence of industry sponsorship and authors’ conflicts of interest on the...
At the beginning of the artificial intelligence (AI)/machine learning (ML) era, the expectations are...
The following manuscript is a scoping literature review which provides a comparative narrative analy...
Contains fulltext : 152571.pdf (publisher's version ) (Open Access)OBJECTIVE: Duri...
Objective: To evaluate clinical trial registration, reporting and publication rates for new drugs by...
In the twentieth century, the Food and Drug Administration (“FDA”) rose to prominence as a respected...
At the beginning of the artificial intelligence (AI)/machine learning (ML) era, the expectations are...
Background: Software as a medical device (SaMD) has gained the attention of medical device regulator...
Objective: To investigate pharmaceutical or medical device industry funding of patient groups. Desig...
Abstract CONTEXT: Disclosure of conflicts of interest (COIs) from pharmaceutical industry study fund...
abstract: The adaptive artificial-intelligence (AI) medical device industry is a novel industry in t...
Protecting and promoting public health is the mission of the U.S. Food and Drug Administration (FDA)...
Background: There has been substantial interest from the pharmaceutical industry to study and develo...
Artificial intelligence (AI) and Machine learning (ML) systems in medicine are poised to significant...
Artificial intelligence (AI) has the potential to make health care more effective and efficient in t...
Objective: To assess the influence of industry sponsorship and authors’ conflicts of interest on the...
At the beginning of the artificial intelligence (AI)/machine learning (ML) era, the expectations are...
The following manuscript is a scoping literature review which provides a comparative narrative analy...
Contains fulltext : 152571.pdf (publisher's version ) (Open Access)OBJECTIVE: Duri...
Objective: To evaluate clinical trial registration, reporting and publication rates for new drugs by...